---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-070285"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:49:53.224919+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company

## Summary
- Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.
- Citius Pharma owns approximately 90% of Citius Oncology after the merger.
- LYMPHIR (denileukin diftitox) approved by FDA for relapsed/refractory cutaneous T-cell lymphoma.
- Citius Pharma made $3.8M capital contribution to Citius Oncology via no-interest promissory note.
- Amended shared services and registration rights agreements executed; shares subject to 6-month lock-up.

## SEC filing metadata
- accession: 0001213900-24-070285
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/0001213900-24-070285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/ea0211482-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-070285
- JSON: https://secwatch.observer/filing/0001213900-24-070285.json
- Plain text: https://secwatch.observer/filing/0001213900-24-070285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.